Advanced cancer is still considered an incurable disease because of its metastatic spread to distal organs and progressive gain of chemoresistance. Even though considerable treatment progress and more effective therapies have been achieved over the past years, recurrence in the long-term and undesired side effects are still the main drawbacks of current clinical protocols. Moreover, a majority of chemotherapeutic drugs are highly hydrophobic and need to be diluted in organic solvents, which cause high toxicity, in order to reach effective therapeutic dose. These limitations of conventional cancer therapies prompted the use of nanomedicine, the medical application of nanotechnology, to provide more effective and safer cancer treatment. Potential of nanomedicines to overcome resistance, ameliorate solubility, improve pharmacological profile, and reduce adverse effects of chemotherapeutical drugs is thus highly regarded. Their use in the clinical setting has increased over the last decade. Among the various existing nanosystems, nanoparticles have the ability to transform conventional medicine by reducing the adverse effects and providing a controlled release of therapeutic agents. Also, their small size facilitates the intracellular uptake. Here, we provide a closer review of clinical prospects and mechanisms of action of nanomedicines to overcome drug resistance. The significance of specific targeting towards cancer cells is debated as well. Among the different cancers, breast, lung, colon, and prostate cancer caused the most cancer death in 2018. In total, cancer related deaths account for 20% of all deaths in Europe. Even though there has been a progress achieved in the development of more effective therapies against cancer, over the past years, recurrence of tumour growth and metastatic spread in the long-term is a common event. Sadly, due to the increased resistance, clinicians have just limited options of effective treatments for secondary tumours. In addition, many classical chemotherapeutic anti-cancer agents kill cancer cells by directly damaging their DNA, which produces high toxicity due to its non-specificity. Also, many effective chemotherapeutic drugs are hydrophobic and need to be diluted in an organic solvent  that causes toxicity when injected. Therefore, an increment of the therapeutically effective dose is not an option. Consequent drug resistance allows the tumour to grow and spread even with the treatment. Cancer resistance can either exist before treatment (intrinsic) or can be generated after therapy (acquired). In addition, heterogeneity among patients and tumours make drug resistance a highly challenging event. Closer understanding of the mechanisms involved in drug resistance is needed in order to achieve better outcomes in cancer treatment.According to the World Health Organization, cancer is the second leading cause of death globally, with estimated 9.6 million deaths in 2016. In Europe, 4.2 million new cases were diagnosed and almost 2 million deaths were caused by cancer in 2018Cancer cells are masters in finding a way to resist the treatment designed to kill them. They may acquire new mechanisms and/or adapt existing mechanisms to protect from the toxic effects of current treatments. Nanotechnology-based drug delivery systems are able to incorporate drugs or gene products with active anti-cancer activity but poor solubility, low bioavailability, or inadequate toxicological profile. In this sense, anti-cancer nanomedicines can improve anti-cancer efficacy mainly by: (1) increasing cytotoxic drug accumulation in tumours thus improving anti-cancer efficacy; (2) prolonging drug systemic circulation, lowering its clearance and decreasing drug accumulation in the normal organs thus reducing undesired toxicity; and (3) deliver different anti-cancer drugs within the same platform. This way higher concentration of chemotherapeutic drugs can be applied, while secondary effects are circumvented. Moreover, multimodal treatment using the same nano-platform could avoid several types of drug resistance . Furthermore, nanotechnology-based drug delivery systems (nano-DDS) are able to incorporate drugs or gene products with active anti-cancer activity but poor solubility, low bioavailability, or inadequate toxicological profile. This may lead to an improved efficacy and a superior bioavailability/biodistribution of the carried compound, opening the therapeutic window.,5,6. When a substrate binds to a transporter, ATP hydrolysis drives a change in conformation that pushes the substrate out of the cell and the concentration of intracellular drug decreases [Figure 1A]. ABC transporters  have a wide substrate specificity and are able to efflux from cells many xenobiotics, including alkaloids, epipodophyllotoxins, anthracyclines, taxanes, and kinase inhibitors. Of note, the most chemotherapy resistant tumours express the highest levels of efflux pumps. Importantly, nanomedicine can bypass drug efflux via ABC transporters since it is internalized by endocytosis. This internalization process increases the intracellular accumulation of the drugs and ensures its release in the perinuclear region, avoiding membrane transporters. Besides surface functionalization, encapsulation of various active therapeutics in a single nanoparticle platform helps to overcome MDR.Cancer cells may acquire multidrug resistance (MDR), since they express various ATP-binding cassette (ABC) transporter family proteins. Identifying patients whose cancer cells over-express a transporter that reduce drug efficacy or has altered expression of other players  is a plausible approach to determine whether a patient would benefit from nanomedicine based drug delivery.Moreover, cells possess a sophisticated mechanism to expel harmful molecules across the plasma membrane. It consists of simultaneous metabolic reactions divided into three phases. Phase I reactions include oxidation, reduction, and hydrolysis of the agents by enzymes that belong to the cytochrome P450 family. In the subsequent phase II, known as consumption and conversion, the main role is played by the glutathione S-transferase (GST) family. They are able to conjugate glutathione (GSH) to a wide range of hydrophobic and electrophilic molecules, making them less toxic, and predisposing them to further modification and being expelled from the cell . This leads to a constant battle between generation of new genetic mutations and generation of new inhibitors that restore drug sensitivity. As an example, the first and second generation of tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, have been ineffective in half of the patients with non-small cell lung cancer (NSCLC) due to T790M gatekeeper mutation in EGFR. Moreover, some patients showed resistance as well to third generation of TKIs like osimertinib and rociletinib via C797S mutation. Both mutations impair the binding of TKIs to EGFR in different way,12. Hence, a fourth generation of TKI (EAI045) has been designed to overcome both T790M and C797S resistance. EAI045 binds to an allosteric site located in EGFR instead of the modifiable ATP sites.Apart from elevated efflux, some drugs are unable to interact with their molecular target  because it has been altered by means of mutations or modifications [Figure 1C]Nanomedicine can in this sense prevent the appearance of secondary mutations via increased dose of inhibitor. Encapsulation of small drug inhibitors and specific targeting may prevent its degradation in the blood stream, accumulation in healthy tissues and thus facilitates higher therapeutic dose while lowering adverse effects.. Together, they are required due to the constant genomic assault that cells undergo from exogenous sources like ionizing radiation and the action of chemotherapeutic drugs, as well as endogenous sources such as free radicals produced during metabolism due to an aberrant DNA replication. For example, platinum-containing chemotherapy drugs such as Cisplatin cause harmful DNA crosslinks leading to apoptosis, but resistance often arises due to nucleotide excision repair and homologous recombination. Therefore, DDR of affected cells to the anti-cancer drugs may result in reduced efficacy of the drugs by DNA lesion repairs, leading to drug resistance [Figure 1D]. The inhibition of DNA repair systems are a possible way to sensitize cancer cells to chemotherapeutic drugs and thus to increase their efficacy. However, although deregulation of DDR may remit the resistance induced by DNA repair, there is a risk. It may also increase the development of new mutations due to genomic instability.Inducing DNA damage is a common strategy of many chemotherapeutics to kill cancer cells. The most detrimental DNA damage is the DNA double-strand break (DSB). Nevertheless, the existence of repair pathways described as DNA damage response (DDR) that maintains genomic integrity is well known. It includes DNA double strand break repair, base excision repair, mismatch repair, and nucleotide excision repair. In 2014, olaparib became the first PARP inhibitor approved by the Food and Drug Administration (FDA) and the European Medical Agency (EMA) as a treatment for metastatic breast cancer for patients with BRCA1/2 mutation. However, its poor water solubility and severe toxicity are two major impediments for the clinical success of olaparib. Encapsulation of olaparib in nano-platform may help to solve both issues. Accordingly, radiosensitization mechanisms and toxicity of olaparib nanoparticles (Ola-NPs) have been already investigated in xenograft mice models. The combination of Ola-NPs and radiotherapy significantly inhibited tumour growth and prolonged survival in mice. Importantly, no additional toxicity caused by Ola-NPs was observed,16. This approach of exploiting DNA repair in additional pathways and tumour types opens a new window to overcome drug resistance in cancer.A successful advance in the field was the characterization of poly(ADP-ribose) polymerase (PARP) in patients with germline mutations in the DNA repair genes BRCA1/2. Tumour cells with BRCA1/2 mutation have an impaired DNA DSB repair and they can only be repaired by PARP-mediated base excision repair (BER). Besides, changes in apoptosis-related proteins can also result in drug resistance. For example, tumour suppressor protein p53 (TP53) promotes apoptosis in response to chemotherapeutics, and when it is mutated, drug resistance increases.Another type of cancer cell resistance linked with DNA damage is resistance to apoptosis. In non-cancer cells, if the DNA damage is not repaired, it produces a cell cycle arrest that drives the cell to a programmed cell death known as apoptosis [Figure 1E]. Also, autophagic cell death induced by nanomaterials alone and as a part of chemo-, radio- and photothermal therapy holds great promise as anti-cancer therapeutic option. Besides, ferroptosis induction by iron-based nanomaterials in drug delivery, immunotherapy, hyperthermia, and imaging systems shows promising results in malignancies.The capability of nanomaterials to induce non-apoptotic forms of cell death has gained widespread attention in cancer treatment. Different nanomedicines can induce programmed cancer death like paraptosis, overcoming apoptosis based resistance and effectively inhibiting drug resistant tumour growth-23. Epigenetic mutations lead to genomic instability and at the same time generates a great level of genetic heterogeneity within the tumours. Therefore, tumours are not a set of homogeneous cancer cells, but they contain various types of cells and extracellular matrixes (ECM) that orchestrate all aspects of cancer hallmarks. Thus, tumours should be considered as a highly complex heterogenic dynamic entity that evolves in time, always trying to adapt and survive in adverse conditions. Among the different cell types, particularly involved are normal/differentiated cancer cells, cancer stem cells (CSCs), normal stromal cells, fibroblasts, mesenchymal cells, and tumour-infiltrated immune cells . During tumour growth, cancer cells and TME constituents are continually adapting to the environment conditions, influencing the overall tumour growth. Because chemoresistance relies in the clonal evolution generated by mutations and phenotypic variants, cancer cell clones develop resistance to the treatment and remain progressing while current treatment eliminates only the sensitive clones. Indeed, after treatment the overall tumour mass may be reduced, but some remaining resistant clones might survive and eventually cause tumour regrowth and relapse. Resultant recurrent tumours are often defined by a very aggressive tumour phenotypes with very limited treatment options.The main mechanism that embraces cancer drug resistance phenotypes  is the epigenetic cancer adaptation,27. This subpopulation of cells has stem cell-like properties like self-renewal, tumour initiation capacity, and long-term repopulation potential. Moreover, CSCs are also capable to overcome hypoxic conditions by entering a stable quiescence state and proliferating afterwards. Additionally, these cells survive in non-attachment conditions and can initiate tumour growth in vivo leading to an increased capacity to migrate, intravasate, and generate metastasis [Figure 3]. Although the total number of CSCs can vary, these features remain constant. It is important to highlight that most of the identified CSC markers are also found in cells with mesenchymal phenotype .Indeed, patients with recurrent resistant cancer show higher numbers of cancer stem cells (CSCs) within the tumour. Growing evidence suggest that CSC populations in the TME share several properties of stem cells. There is a direct correlation between cancer recurrence and metastatic growth with the increase of the percentage of CSCs in the tumour. Its importance in oncology relies in the inner capacity of resistance to drugs and toxins through the expression of the different mechanisms described above, such as over-expression of multidrug resistance channels, enhanced DNA repair, impaired apoptosis, and over-expression of detoxifying enzymes like aldehyde dehydrogenase 1 (ALDH1A1) and bleomycin hydrolase (BMLH)etc.) and an increase in mesenchymal markers .To be able to enter systemic circulation and generate metastasis, the cancerous cells need an essential process for tumour progression known as epithelial to mesenchymal transition (EMT). It transforms epithelial cancer cells into a mesenchymal phenotype, promoting local invasion and dissemination to distal organs. This process involves loss of cell-cell adhesion and apical-basal polarity in epithelial cells, followed by a gain in their ability to individually migrate and invade. This conversion correlates with a decrease in epithelial markers  abolish this CSC population [Figure 4].Further, it has been reported that CSC phenotype within a tumour is a bidirectional dynamic progress and there is an equilibrium between CSC and non-CSC populations to maintain a constant level of these cells. For example, IL-6 secreted by non-CSC induces formation of breast CSCs with OCT4 expression. At the same time, OCT4 over-expression is induced via IL-6-JAK1-STAT3 signalling pathway to maintain dynamic equilibrium, reported .Nowadays, new strategies for cancer treatment focusing into modulating tumour cell inter-communication and the possibility to modulate the composition of the TME, are being explored. Nanomedicines, dues to its ability to target specific cell types or to deliver multivalent treatment, have gained a lot of attention within the field. Also use of nanomedicine in combination with classic chemotherapy is being explored in order to prevent CSC dynamic phenotype. Many proteins and enzymes involved in regulatory pathways remain inaccessible because of their cellular location, binding, and/or function . Alternatives have been screened to generate a therapeutic effect over undruggable targets. One of them is the modulation of signalling pathways using nucleic acid therapeutics (RNA and DNA). However, these therapies reported low transfection efficiency and loss of activity in vivo due to their poor stability and rapid degradation. Among nucleic acid therapies, RNA molecules have emerged as a new class of therapeutics that may permit the re-targeting of mutated targets, which holds great promise to expand the range of druggable targets, from proteins to RNAs as well as the genome. The use of RNA in gene therapy is increasing due to its unique features compared to DNA. It has transient expression which makes it safer because it does not integrate into the host genome and therefore, there is no risk of insertion mutagenesis. Nonetheless, the clinical application of RNAs as a therapeutic tool is limited by its instability and also by its ability to activate immune responses. The design of suitable vehicles for RNA thus results essential for this kind of therapies. Moreover, a vehicle (drug delivery system) may also allow RNA to cross cellular barriers and further, improve blood stability for the molecule. In addition to nucleic acid therapies, anti-cancer drugs with poor in vivo delivery may also be incorporated in nano-DDS.Cancer therapeutics interact with their corresponding molecular target to perform their pharmacological actions, which are necessary for the control of disease. Among the different biologic molecules, proteins translated from mRNAs are common targets of therapeutically active small molecules. However, the majority of proteins encoded by the human genome cannot be targeted by conventional therapeutics and therefore, are considered non-druggable. However, these agents are exposed to degradation and various mechanisms of clearance. Therefore, deliver the RNA to the correct place into the correct cells is a great challenge. In order to reach the cells, nanomedicine can be an alternative because nanosystems can protect them from environmental degradation and drive them to target sites. Many nanomaterials take advantage of the high negative charge of nucleic acids by complexing them electrostatically with cationic materials. For example, positively charged polymers like poly(l-lysine) (PLL), polyethylenimine (PEI), polyamidoamine (PAMAM), and poly(beta-amino ester)s (PBAEs) can bind nucleic acids into nanoparticles via electrostatic interactions with amines. Similarly, cationic lipids have been used recently to encapsulate multiple types of nucleic acids. However, to date, no nanomedicine with a gene delivery approach has been approved by the FDA or EMA to treat cancer. Nevertheless, interesting studies have shown substantial promise. An amphiphilic-based gene delivery system that combines pluronic F127 micelles with polyplexes, spontaneously formed between anionic siRNA and cationic PEI by electrostatic interaction. The system was loaded with a siRNA against AKT2 which is an important oncogene with a special role in CSC malignancy involved in breast cancer. Results showed a significant reduction on cell invasion capacity and strong inhibition of mammosphere formation  after treatment, in CSC isolated from MCF-7 and MDA-MB-231 breast cancer cell lines. Similarly, RGD-targeted chitosan nanoparticles containing siRNA have been used to successfully downregulate drug efflux transporter P-glycoprotein expression and reverse multidrug resistance in a breast cancer model. Furthermore, the first targeted, polymer NP carrying siRNA administered to humans was CALAA-01. It is formulated with cyclodextrin-containing cationic polymer, a PEG-corona, and human transferrin (Tf) as a targeting ligand. This ligand binds to over-expressed transferrin receptors (TfR) on cancer cells and triggers cellular uptake. Its function is to silence the expression of the M2 subunit of ribonucleotide reductase. CALAA-01 is still in human trials with promising results. The same targeting ligand has been widely used in other targeted formulations such as SGT-53. It is in phase I and II trials for the treatment of solid tumours, glioblastoma, and metastatic pancreatic cancer. It is a complex composed of a wild type p53 gene [plasmid DNA (pDNA)] encapsulated in a liposome, which is a well-known tumour suppressor gene. Numerous tumours possess a loss or mutation of wild type p53. Similarly, SGT 94 with the same platform and targeting ligand as SGT-53, contains RB94 gene (pDNA), a tumour suppressor gene. RB94 gene has shown enhanced tumour suppression and tumour cell killing activity in all tumour cell types studied to date, including bladder cancer cell lines.RNA therapies in cancer treatment can be divided into three categories: those that target nucleic acids (either DNA or RNA), those that target proteins, and those that encode proteins (mRNA). There are two RNA therapies that target nucleic acids which are widely used for cancer treatment: single-stranded antisense oligonucleotides (ASOs), and double-stranded nucleotides that operate through RNA interference (RNAi). The first one consists of a set of nucleotides that prevent mRNA from being translated into protein. They can block the start of translation or mark the mRNA for degradation. RNAi therapies involve small interfering RNAs (siRNAs), and microRNAs (miRNAs), to also degrade mRNA and prevent it from being translated into proteinfirst-in-class liposomal NP-formulated RNAi therapeutic in patients with cancer. It contains siRNAs targeting VEGF and kinesin spindle protein (KSP) and was tested in a phase I clinical trial for patients with advanced solid tumours with liver involvement. The promising use of siRNA delivered by liposomal formulations was followed by Atu027. It consists of a liposomal siRNA, which silences the expression of protein kinase N3 in the vascular endothelium. A phase I and a phase II clinical trial, Atu027 in combination with gemcitabine, has been performed in patients with advanced solid cancer and advanced metastatic cancer. Also, liposomal-siRNA formulations continued to develop, such as EPHARNA and TKM-080301 with anti-EphA2 and anti-PLK1 siRNA, respectively,39. Sadly, the clinical trial of the liposomal micro-ribonucleic acid-34 (miR-34) was withdrawn in phase I due to immune related serious adverse events (NCT02862145).In this context, ALN-VSP was a novel .Finally, regarding inorganic NPs some attempts have also been done to deliver siRNA. An example is NU-0129, composed of siRNA against BCL2L12 bound to gold NPs. This formulation is being investigated in patients with recurrent glioblastoma. Besides, their polydispersity index (PDI) value should be close to 0, indicating that batch samples are monodisperse, since even small variations in PDI may cause dramatic changes in biocompatibility and toxicity. Cellular uptake and biodistribution is determined also by the surface charge. In general, positive charges facilitate cell internalization compared to neutral and negatively charged nanoparticles but are often more toxic. Surface charge also affects their interaction with the biological environment and their binding with blood proteins  forming a specific protein corona surrounding the nanoparticle. In this context, corona formation might modulate the pattern of hemolysis, thrombocytosis activation, and cellular uptake of the nanoparticles. This may be partially solved by the use of poly (ethylene glycol) (PEG) in the surface of the drug-delivery system. PEGylation has the ability to enhance NP retention time. Basically, it prolongs the circulation time by increasing its hydrophilicity and reducing the rate of glomerular filtration. Furthermore, it forms a hydrophilic shield that is able of masking the antigenic sites of the proteins and provide protection from reticuloendothelial cells, proteolytic enzymes, and phagocytes. Therefore, it delays recognition by the immune system and increases the chance of NPs to target the desired tissues/cells.Among the various existing nanosystems, nanoparticles (NPs) have the ability to transform conventional medicine by reducing the adverse effects and providing a controlled release of therapeutic agents. There are different requirements in NPs to be used as delivery systems that include size, biocompatibility, and surface chemistry, to prevent unspecific interactions. Ideally, synthesized NPs must remain stable in the blood stream until they reach cancer cells within the TME. They should be able to escape as much as possible from the reticuloendothelial system (RES) and the mononuclear phagocyte system (MPS) to reduce their body clearance. To do so, most systemically administered nanoparticles are greater than 10 nm to prevent premature excretion by kidneys, and below 200 nm to be able to pass through the microcapillaries without producing embolism. The most used nanoparticles in the clinics for oncology applications are liposomes, polymeric NPs, protein-based NPs, and inorganic NPs.The NPs can be made from a variety of materials. To date, they are classified into five categories: lipid-based NPs ], polymer-based NPs , inorganic NPs , drug conjugates , and viral nanoparticles [Table 1].Liposomes are frequently used in nanodrug formulations due to their unique properties. They consist of a self-assembling spherical vesicle composed of a lipid bilayer membrane arranged around an empty core that can carry either hydrophilic or hydrophobic compounds. Liposomes can also accumulate at the site of a tumour and deliver higher drug loading. They can also be generated to be temperature- or pH- responsive using lipids of different fatty-acid-chain lengths. This permits the controlled release of their contents only when exposed to specific environmental conditions. However, liposomes have short circulating times due to rapid clearance. This problem has been minimized by PEGylation of the liposome surface as previously mentioned . However, toxicity issues such as hypersensitivity reactions have been reported,47. SLNs have an improved safety profile, high stability, controlled release, easier scale-up and low-cost production. However, they have also limitations because there is a risk of polymorphic transitions that can cause problems in stability, drug leakage, and particle size increase.Recently, SLNs, which are made of solid lipid matrix and a surfactant layer, have gained attention because they present advantages in respect to conventional and stealth liposomes. As an example, encapsulation in SLN of erlotinib (a TKI) and gemcitabine (a chemotherapeutic agent), commonly used in the treatment of NSCLC, have been reported. The formulations showed an improved therapeutic effectiveness and enhanced safety when used against human alveolar adenocarcinoma epithelial A549 cell line.Polymer-based NPs are easily synthesized in a wide range of sizes through organic synthesis methods and are commonly used in nanomedical research. Polymers can be natural, synthetic, or pseudo-synthetic. Polymeric NPs are suitable for controlled release applications, for increasing circulations time and drug half-life, and for increasing biocompatibility and solubility without body accumulation. Nevertheless, there are relevant issues regarding the limited shape and broad size distribution of current formulations. Polymeric NPs are typically spherical, while a wide variety of different sizes may be generated during synthesis. Among the different polymeric approaches, micelles are self-assembling polymeric amphiphilic NPs that can be customized for a slow and controlled delivery. They can achieve different particle size, drug loading, and release characteristics depending on their composition. Micelles have a hydrophobic internal core, which can be used to encapsulate drugs that have poor solubility to allow dissolution in aqueous solutions. Polymeric micelles that encapsulate highly hydrophobic zileuton, a potent inhibitor of CSCs, showed significant reduction of CSCs percentage within tumours and effectively reduced the number of circulating tumour cells (CTCs) in the blood stream and the spread of metastatic cells. The clinical use of Nab NPs currently marketed will be discussed in the next chapter. Further, gemcitabine, a first-line therapy for pancreatic cancer, has been also successfully loaded in human serum albumin NPs and showed strong inhibitory effect on tumour growth against the pancreatic tumour cell line BxPC-3 both in vitro and in vivo.Of note, within this NP category, Nab technology emerged when researchers exploited the properties of proteins found in the blood serum that would facilitate transport and dilution of drugs during circulation. In this context, albumin has a number of characteristics that make it an attractive drug carrier and has been particularly used in oncology. Indeed, it is a natural carrier of endogenous hydrophobic molecules such as vitamins and hormones. Therefore, poor water-soluble molecules are attached to albumin in a reversible non-covalent manner. Indeed, polymer-drug conjugates are widely used in preclinical studies such as N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-cyclopamine conjugate (P-CYP) against CSCs and HPMA copolymer-docetaxel conjugate (P-DTX) against bulk tumour cells, both tested in prostate cancer cell lines (PC-3).Active agents may also be covalently linked to antibodies (antibody-drug conjugates) and to peptides (protein-drug conjugates). Moreover, therapeutic proteins as active agents can also be linked to polymers (polymer-protein conjugate). The conjugates are intended to improve the delivery of drugs into desired tissues or cells without necessarily impacting drug solubility, stability, or biodegradability. In contrast, nanocarriers based on lipids, proteins, glycans, or synthetic polymers, usually encapsulate the drug and therefore avoid the need to covalently link the drug to the carrier.In addition to organic NPs, a large number of inorganic materials, such as metal oxides, metal, or silica, can be used to create NPs. Specifically, metal and metal oxide NPs are in the focus for their potential use in therapeutic and imaging applications. Superparamagnetic iron oxide nanoparticles (SPIONs) are gaining attention because they show low toxicity, long circulation times, and are often biodegradable. Also, gold has a unique combination of thermal and optical properties which are relevant to design better theragnostic applications. Properties of gold NPs can be modulated by changes in their physicochemical characteristics . Excitement of electrons in gold NPs by electromagnetic radiation can generate a considerable amount of energy. In fact, colloidal gold NPs act as excellent radiosensitizers when exposed to high-energy electromagnetic radiation. Also, silica NPs have emerged as an interesting candidate for anti-cancer therapy owing to its biodegradability, rapid release kinetics, and purpose driven tissue distribution. They are often used in imaging techniques, while their structure and porosity permit the loading of different drugs. For example, doxorubicin delivery via folate-targeted mesoporous silica nanoparticles (MSN) greatly improves the efficacy of the free drug in a xenograft tumour model.Moreover, carbon nanotubes are carbon cylinders composed of benzene rings that have interesting structural, mechanical, electrical, and optical properties for drug delivery and potential new therapies purposes. For example, the anti-cancer drug combretastatin A4 (CA4) was covalently linked with single-walled carbon nanotubes (SWCNT) with a superior cell cycle arrest than the free CA4. For example, pox viruses such as myxoma or vaccinia strains, which preferentially replicate in tumour cells due to specific features of cancer cells such as blockage of apoptotic pathways, deregulation of cell replication machinery, and immune evasion. The synthetized pox virus JX- 594 was designed to replicate in tumour cells and destroy them via activation of the EGFR-Ras-MAPK signalling pathway. Unfortunately, despite the remission observed in some patients, flu-like symptoms and hyperbilirubinemia were common side effects. Among the different oncolytic viruses currently tested, none have yet reached the market. Their major drawbacks are concerns about biosafety and cytocompatibility.Due to the inherent infective properties of viruses, many researchers are using tumour-homing viruses engineered to express therapeutic proteins as anti-cancer therapies. Nowadays, it is still widely used for its original indication and to treat breast and ovarian cancer, and multiple myeloma as well. Furthermore, Abraxane, a formulation of paclitaxel (PTX) complexed with albumin bound nanoparticle was approved by the FDA in 2005 to treat metastatic breast cancer since substantial reduction of toxicity was demonstrated. Because of its high hydrophobicity, PTX has to be diluted in polyethoxylated castor oil  producing strong systemic and neurological toxicity. The increased tolerance of Abraxane which does not use Cremophor, implies better safety profile and allows the administration of higher doses of PTX, yielding greater efficacy.The first nanoformulated drug approved by the FDA was Doxil [Doxorubicin hydrochloride in PEG coated liposomes ] to treat Kaposi’s sarcoma in patients with human immunodeficiency virus (HIV) in 1995 . Also, Apalea is a recently EMA approved micelle formulation of paclitaxel to treat ovarian cancer.As stated earlier, the most well-established polymer used for drug delivery is PEG. It is used in clinically approved polymer-drug formulations like Oncaspar, a PEGylated L-asparaginase to treat acute lymphoblastic leukemia. To achieve intra-tumoural hyperthermia, a magnetic field is applied to heat nanoparticles injected into the tumour. The generated heat is enough to cause programmed and nonprogrammed cell death.Regarding inorganic nanoparticles, and specifically SPIONs, Nanotherm has been approved by EMA in 2011 In the same context, gold NPs are also promising as antineoplastic agents either alone or as drug delivery vectors. As mentioned earlier, colloidal gold NPs have been successfully tested against brain tumours as Nanotherm (iron oxide NPs). However, to date, there are no inorganic NPs approved by the FDA or EMA for drug delivery purposes in cancer.. Following Vyxeos, a formulation of solid lipid nanoparticles for the co-delivery of paclitaxel and α-tocopherol succinate-cisplatin prodrug has been also developed in order to achieve synergistic antitumour activity against cervical cancer. It exhibited high tumour tissue accumulation, superior antitumour efficiency, and lower in vivo toxicity.Regarding combination therapy, Vyxeos (CPX-351) was the first dual - drug liposome approved by FDA in 2017 . Similarly, it has been proposed the use of PLGA-PEG-PLGA NPs to co-encapsulate 5-FU and Chrysin, a natural compound known to enhance the therapeutic efficacy of chemotherapy in colon cancer HT29 human cell line. NPs loaded with both 5-FU and Chrysin were found to have significantly higher growth inhibitory effect.Preclinical co-delivery studies with polymeric nanoparticles have also been reported. For instance, the co-encapsulation of rapamycin in combination with the chemosensitizer piperine in Poly (PLGA) NPs. Piperine is known to be a P-glycoprotein (ABCB1) inhibitor, one of the most studied MDR channels mentioned in the previous chapter. The formulation showed an improved bioavailability and efficacy in the treatment of breast cancer. Another one is Thermodox which consists of a liposome-bound doxorubicin formulated with thermally sensitive lipids. There is a disruption of the lipid bilayer when the lipids are exposed to high heat. There are several clinical trials combining Thermodox with radiofrequency ablation in hepatobiliary tumours and most recently, in breast cancer. Furthermore, a liposomal SN-38, an active metabolite of the topoisomerase inhibitor irinotecan, is also being studied in metastatic colorectal cancer.Nanoparticles are in constant development to improve the current treatments and provide better clinical outcomes. Increasing numbers of clinical trials are taking place . Recently, a phase II trial has successfully concluded in NSCLC (NCT01380769). In addition, the same polymer conjugated with docetaxel named CRLX301 is also being studied in a phase I/II clinical trial in patients with advanced solid tumours (NCT02380677). Furthermore, a micellar formulation of cisplatin , is being investigated in several phase I clinical trials studying its use alone or in combination with other chemotherapies.Regarding polymeric nanoparticles, Opaxio is one of the most promising nanomedicines. It contains polyglutamic acid-conjugated (poliglumex) paclitaxel. It has shown potential in the treatment of ovarian cancer. A randomized phase III study in women with advanced ovarian, primary peritoneal, or fallopian tube cancer is undergoing (NCT00108745). CRLX101 is a polymer - drug conjugate formulation of camptothecin, a topoisomerase I inhibitor, and a cyclodextran-PEG polymer which is being studied alone and in combination with other drugs in numerous phase I and II clinical trials in the treatment of lung cancers, gynecological malignancies, and solid tumoursRegarding the inorganic NPs, as mentioned previously, non of the gold NPs have reached the market so far. Nonetheless, they have shown promise as antineoplastic agents. For example, gold NPs have been studied in a phase I clinical trial as a drug delivery vector of the toxic antitumour agent tumour necrosis factor alpha (TNFα)  constituted by a recombinant human TNFα attached to gold NPs using a PEG linker (NCT00356980).. This effect relies on the specific pathophysiological characteristics of the tumour vessels generated by angiogenesis to provide nutrients to the malignant cells. The abnormally wide fenestrations found in these blood vessels due to the production of vascular permeability factors facilitate the extravasation of NPs. The lack or defective lymphatic drainage that characterizes tumour sites also facilitates NPs extravasation [Figure 5]. However, there are evidences that show a great variability in the EPR effect among patients and tumour types due to tumour heterogeneity and differences in vascular permeability,70.A majority of nanoparticles  and 3 ar.After the approval of Abraxane and the prominent use of antibody-drug conjugates in the clinics, researchers nowadays tend to use engineered complex targeted particles instead of unmodified proteins. Tumour cells over-express a wide range of molecules in their membrane that can bind to different antigens and regulate tumourigenic pathways, such as angiogenesis or growth metabolic pathways. It is fundamental for an active targeting to use NPs conjugated to a targeting moiety that binds to the surface of specific cell types, such as tumour cells [Figure 5]. Through surface modification, the NPs properties can be enhanced. The chemistry behind this functionalization determines the interaction of the NPs with the biological environment. Using different strategies, nanoparticles can be functionalized with a variety of ligands such as small molecules, surfactants, dendrimers, polymers, and biomolecules. Functionalization of NPs involves conjugation of molecules to the surface of the particles that can be performed by different approaches. Conjugation can be done through noncovalent interactions by attaching specific ligands through affinity-based systems. They include electrostatic interaction, π-π stacking, and entrapping biomolecules in biocompatible films like phospholipids, polymer, and more. As an example, it has been reported that tRNA molecules can be noncovalently attached to chitosan NPs through G-C and A-U base-pair electrostatic interactions.One of the main challenges in the field is the engineering of targeted DDS capable of specifically binding cancer cells and avoiding non-cancerous ones. The principal factors that control this targeting are the surface functionalization on the NPs, their physicochemical properties, the specificity of the targeting moiety, and the pathophysiological characteristics of the tumour microenvironment (TME). Indeed, NPs interact with the host environment including a great variety of cells, substrates, and other molecules. This interplay could limit their use in specific applications. However, these drawbacks can be manageable by functionalizing the NPs. As stated earlier, some NPs improve their capacities by coating the surface with PEG polymer. This coating can also introduce functional groups. Coupling targeting moieties on PEGylated NPs enhances the targeting of tumour cells. In this regard, surface coating confers additional functionality to the NPs, and it allows targeting as well. NPs can be coated with organic (monomer and polymer) and inorganic  layers. The different functionalization approaches provide a wide range of potential surface modifications of NPs to enhance their capacities and molecular biological applications.Furthermore, it is also possible to perform a direct binding of the molecule of interest to the desired ligands on the NPs surface by covalent conjugation. This approach involves linkage reaction supported by a catalyst. Covalent linkers can be used to form poly (PLGA) - siRNA conjugates for efficient release of siRNA molecules. They play a key role in cellular uptake because the multiple interactions of NPs to target a specific cell membrane induce agglomeration of receptors that facilitate endocytosis. Therefore, optimal parameters vary depending on the size, shape, and material composition of the particle as well as the chemistry of the particular target ligand. Independent of the conjugation method used, the functionalization of a NP with a ligand can facilitate binding to a biomarker specifically over-expressed in targeted cells. Among the different ligands, the most used are antibodies, proteins, peptides, small molecules, and aptamers.The conjugation process is very complicated because it is important to keep the efficiency of the system unchanged. However, the conjugation can modify the physicochemical properties of NPs, such as size, shape, and others. Other physicochemical properties to take into account are density, orientation, or charge of ligandsin vivo, the interaction between a ligand and a receptor can be used to improve the internalization of the nanomedicine in tumour cells at the tumour site. As described above, beyond the function in the identification of the malignant cells, active targeting  facilitates cellular uptake as a result of receptor-mediated endocytosis.Even though the use of active targeting does not seem to be able to significantly change the accumulation of NPs by EPR effect at the tumour sites . Additional liposomal nanoformulations, such as 2B3-101 and MBP-426, are currently undergoing clinical evaluation for brain and solid tumour treatments, respectively. The first one targets the glutathione transporter and the second one the transferrin receptor. Anti-EGFR ILs-DOX is another liposomal NP which is loaded with doxorubicin and has an antibody against EGFR as a targeting ligand and is being studied in patients with gliomas (NCT03603379). Also, a phase II study in patients with metastatic castration-resistant prostate cancer (NCT01812746), was performed with the targeted polymeric nanoparticle BIND014, a docetaxel encapsulated PLGA-PEG NPs targeted to prostate-specific membrane antigen (PSMA). The study outcomes showed reductions in prostate specific antigen (PSA) related to cancer, radiographically confirmed disease control in bone and visceral metastatic disease, favourable CTC conversions, and an acceptable adverse effect profile. However, the response rate was lower than expected. Because of this, a randomized phase III compared with the standard docetaxel, which is widely used and effective, will be highly challenging. Moreover, the role of PSMA is still not well elucidated and would require additional studies. Due to the importance of targeting cancer resistance mechanisms, a p-glycoprotein targeting micellar formulation of doxorubicin (SP1049-C) is undergoing clinical evaluation. It is currently in phase II to treat patients with advanced adenocarcinoma of the oesophagus.Because receptor-mediated endocytosis helps NPs avoid MDR complexes, active targeting might improve cell internalization and therefore, help to overcome drug resistance of metastatic cancers. Thus, there are many nanoformulations with active targeting being studied with the purpose of reducing drug resistance while increasing the effective amount of drug delivered to the tumour cell . However, as promising as targeted therapies may seem, increasing the efficacy of the treatment is still challenging. An example is MM-302, a HER2-targeted PEGylated antibody-liposomal doxorubicin conjugate that targets HER2 over-expressing tumour cells. Although phase I results in HER2-positive metastatic cancer patients were promising, Phase II studies were stopped because they could not demonstrate the benefit over the current treatments with trastuzumab and pertuzumab.Regarding drug conjugates, Sacituzumab-govitecan (IMMU-132) is a new antibody-drug conjugate targeting the human-trophoblast-cell-surface antigen 2 (Trop-2) conjugated with the active metabolite of irinotecan (SN-38). Trop-2 over-expression is related to invasiveness and poor prognosis in multiple human carcinomas. A phase II study in patients with uterine and ovarian carcinosarcomas is undergoing. Another example is the use of the antibody CAB51 against human epithelial growth receptor 2 . It has been linked to cationic SLNs to evaluate the potential of targeting SLNs against breast cancer cells. The effect on MCF-7 and BT-474 cells showed a clearly increased level of NPs internalization. Regarding functionalization with aptamers, there is a highly water-soluble nucleolin aptamer (NucA) paclitaxel conjugate that delivers PTX to the tumour site. NucA interacts with nucleolin protein which it is found expressed on the surface of cancer cells. Thus, NucA could be a promising tumour-targeting element for developing paclitaxel derivatives. The most used glycoprotein for active targeting is transferrin because its receptors are known to be over-expressed in cancer cells surface. An example is the encapsulation of monomyristin, a monoacylglycerol that activates the intrinsic apoptotic mitochondrial pathway in HeLa cells, into dextran-covered polylactide (PLA) NPs functionalised with transferrin.In comparison with the number of undergoing clinical trials, there are much more pre-clinical studies regarding targeted nanomedicines being reported. Available data in breast and colon cancer cell lines show that specific targeting can enhance the performance of nanomedicines and sensitizes CSC to paclitaxel based chemotherapy.As stated, combination therapy is a promising approach that can be enhanced with the utilization of specific targeting to overcome resistance of tumour cells. In one study, a biotin-/lactobionic acid modified PEG-PLGA-PEG copolymer with curcumin and 5-fluorouracil was synthesized to enhance the treatment of hepatocellular carcinoma. The dual-targeting and drug-loaded co-delivery nanosystem showed an increased cellular uptake and higher cytotoxicity of tumour cells. Therefore, dual-targeting strategies with co-delivery of therapeutics in a single nano-carrier can be used to achieve better intracellular delivery and synergistic anti-cancer efficacyin vivo), the interference of biological barriers, the misinterpretation of drug delivery concepts, a poor cost-effectiveness ratio, and a variety of manufacture and scale-up difficulties. Besides, the engineering of a DDS with active targeting might increase the complexity and potential immunogenicity of the whole system. Also, it makes it more difficult, time consuming, and expensive to develop. In addition, numerous limitations exist for clinical applications of some active targeting drugs because of their rapid elimination by the reticuloendothelial system and high tumour interstitial fluid pressure. A lot of efforts are devoted to developing the “perfect NPs” with a wide range of specific ligands in their surface during preclinical development. It is fascinating what bioengineering is capable to achieve and all the complexity that can be designed and synthesized in a single platform. However, over the last years it has been demonstrated that translation to clinical use gets poorer when complexity gets richer. Up to date, the most clinically successful NP is Abraxane. This albumin-bound paclitaxel NP is a simply engineered NP; however, it is very elegant since albumin is recognized by gp60 receptors of the endothelial cells that guide the extravasation of Abraxane. Many methods of functionalization are published, but most of them lack reproducibility. The functionalization process is very complicated and requires different conditions for each efficient surface modification. It involves a multi-step processing to formulate complex targeted NPs which in turn compromises final production yields. Also, it is important to not forget that even the exhaustive processing for the synthesis of NPs, obtaining uniform size is not yet a reality. Due to the process variation there is a lack of scalability that prevents large-scale manufacturing. It is important to develop highly reproducible single step methods to functionalize NP surface. Further complication is presented by the biological conditions of the tumour. Even though the presence of the EPR effect, for certain NPs to reach and enter the TME may be a considerable challenge. Even though the NP extravasate into the tumour vicinity, targeted NPs commonly bind cells with high affinity in the outer layer of the TME. Thus, they cannot easily penetrate to the inner parts of the tumour. This phenomenon is known as the binding site barrier (BSB) which prevents deeper penetration of NPs into the tumours. Specifically, the BSB limits NP diffusion trough the TME and results in unintended internalization of NPs by stromal cells located near blood vessels. The major components of the BSB are tumour activated fibroblasts. The proximity to the blood vessels and the expression of protein receptors also complicate the penetration of NPs into tumours. Tumour activated fibroblasts need to be considered to overcome the BSB and be able to reach the desired cells in the TME. In addition, TME is also crucial as a player of treatment resistance of many cancers. Moreover, the best strategy to prevent tumour remission should be the elimination of all aggressive cells within the tumour. This could be achieved by the combination of various therapeutic molecules and a combination of gene therapy approaches.Even though promising preclinical data regarding the use of targeted nanomedicines has been achieved, the clinical outcomes are still modest. There are several reasons for the limited clinical translation of targeted cancer nanomedicines. Some of them include the poor understanding of the biology , cytokine-mediated inflammation and cytokine storming, pyrogenicity, and anaphylaxis and other complement activation mediated reactions, as well as recognition and uptake by the cells of the MPS.Further, there is an actual unmet need to synergize passive and active targeting to improve the accumulation of nanoparticles at the desired site while at the same time enhancing their intracellular penetration. Although there are current standard methods, they are insufficient to address the broad spectrum of biomarkers that indicate NP immunotoxicity. In addition, there is an absence of consensus on well characterized reference materials. Therefore, preclinical studies often depend on nanomedicines with known clinical immunotoxicities . Again, the use of immunosuppressed animals makes it even more difficult to determine immunotoxicities related to NPs. Similarly, in clinical studies, patients are premedicated with immunosuppressors to prevent adverse reactions. Screening for these toxicities in preclinical development would help to prevent potentially toxic formulations. However, currently, the properties of nanoparticles  have not yet been fully exploited.In fact, there is a wide variety of nanomaterials available and their physicochemical properties  play an important role in the activation of an immune response. Moreover, the introduction of a targeting ligand changes the properties of the NPs and often makes them even more difficult to pass unnoticed. One of the grand challenges in the NP characterization is screening for immunotoxicities. These studies are based on the estimation of immunoreactive contaminants, such as excipients and linkers. On the contrary, more complex economic considerations are involved when developing a nanodrug that contains a new chemical entity. Moreover, the complexity to design a specific ligand and the conjugation techniques make the whole process more expensive with a difficult scale-up. The cost of using complex chemistry, controlled quality manufacturing, and scaled production is elevated. In addition, the lack of specific general protocols for the study of safety or efficacy of these nanomedicines is hampering clinical development. Apart from all the high costs involved, regulatory requirements also make market entry difficult. Various regulatory agencies like EMA and FDA started their discussion on the classification of nanomaterial and how to regulate them to ensure proper efficacy and safety of these materials. For example, the regulatory system in Europe allows the marketing authorization applicants to receive scientific counselling during early stages of research and development. Also, the Nanotechnology Characterization Laboratory at the National Cancer Institute in the US collects all the data on nanomedicines in oncology. Indeed, integration between materials and translational issues, such as more appropriate disease models, are essential for developing accurate regulation of nanomedicines. Actual mice models used in cancer nanomedicine present some drawbacks in terms of physiopathological properties, as mentioned in the previous chapter. The use of patient derived xenografts (PDX) is a promising alternative to better mimic human TME and study the accumulation and extravasation of NPs as well as specific targeting in a more real-life environment. However, the need to use immune-supressed models is again a drawback because mice lacking an immune system hamper the study of the interactions among NPs, cancer cells, and immune cells in the TME. Still, in order to represent the heterogeneity of human tumour and the drug sensitivity ranges, it is important to create a large bank of PDX of different tumour types. Recently, immunodeficient mice engrafted with human immune systems have been established and are a powerful tool for the next generation of PDX models. The immune deficient mice are irradiated by gamma irradiation and then, human hematopoietic stem cells (HSCs) are introduced in the immune deficient mice to obtain a humanised mouse model. Finally, with the insertion of small parts of the human tumour the result is a PDX model with a human immune system. For example, it has already been reported, a triple negative breast cancer PDX model with humanized mice that provides evidence that supports its use for the pre-clinical investigation of immune-based therapies. Unfortunately, currently expensive production costs of these models limits their wider use.Investment in nanomedicine in the early 2000s accelerated the development of nanoformulations that are currently available in the market. However, even with the sales success of some of them , there are financial challenges that hamper the development of new nanoformulations. As it has been previously explained, it is not easy to demonstrate improved efficacy and safety compared to other validated and marketed products for the same indication. Indeed, the majority of approved nanodrugs are based on currently approved drugs which faces reduced financial risk because the efficacy and safety of the active ingredient had already been established. This poor clinical translation is also seen in the total number of clinical trials (only 2%) in comparison with the total number of publications in the field of cancer nanomedicine. It is necessary to promote the entrance of new products in clinical phases. Many alternatives have been screened to provide a safer and a better DDS treatment. Hydrogels are three-dimensional networks formed by hydrophilic polymer chains build in a water-rich environment which possess a broadly tuneable physical and chemical properties. They are formed through the cross-linking of hydrophilic polymer chains. The water-rich nature of hydrogels makes them widely applicable, including for drug delivery. Their advantage against active and passive nanomedicines is that they can provide localized and targeted therapy regardless of the blood supply and microvasculature morphology of the tumour. Also a hydrogel-based system could extend the physical stability of chemotherapeutic agents or nucleic acids for months. In addition, hydrogels can deliver two or more therapeutic agents in the same platform in a sustained manner. Co-delivery of multiple therapeutic agents with different targets is known to be a promising strategy to overcome drug resistance and reduce the chance of metastatic progression. Recently, paclitaxel and lapatinib NP in a thermosensitive hydrogel showed a synergistic effect. Also, RNAi-chemotherapeutic drug combinations can effectively overcome tumour resistance to chemotherapeutic agents by inhibiting the mentioned multidrug resistance pathways. For example, protein kinase B (AKT)-targeted gene therapy along with paclitaxel given as linoleic acid-coupled pluronic hydrogel showed possible synergistic anti-cancer effects by downregulation of AKT signalling and facilitation of apoptosis induction.All mentioned drawbacks translate into poor clinical outcomes, particularly of targeted therapies. Thus, there is a clear need to focus on existing nano-carriers, combination therapies, patient selection, and ways to enable rapid and more efficient clinical translation. In cancer development, exosomes are further described as mediators of tumour-stroma interaction known as tumour-derived exosomes (TDEs). This crosstalk is known to be involved in various pathophysiological processes including migration, treatment resistance and metastasis. TDEs have the capacity to induce EMT and enhance migratory activity. This was observed in glioblastoma cell lines, lung carcinoma cells, and a model of gastric cancer in vivo. This communication may confer epigenetic changes in the neighbouring cells by transportation of miRNAs. For example, exosomal miR-23a supports the EMT-promoting effect by inhibiting E-cadherin synthesis in lung carcinoma and melanoma cells. TDEs from tumour cells that have undergone EMT can in turn stimulate neighbouring cells to acquire EMT like features. This may explain the communication in the TME between DDC and CSC to undergo conversion and maintain a dynamic phenotype. In addition, the miRNA secreted by TDEs influence cell invasion and intravasation to blood vessels. For instance, exosomal miR-105 in the serum of patients with breast cancer is a prognostic marker for the later development of metastasis. Exosomes can also transport classical chemotherapeutics  to the tumour cells with a reduction of toxicity, such as the one reported in drug-resistant lung cancer cells. Moreover, exosomes can also transport nucleic acids and be used as a vector for gene delivery purposes to the tumour cells. Also, they can be further engineered to present on their membrane targeting ligands to improve biodistribution. The metastatic location is not chosen randomly, instead it is rather a consequence of a tumour-stroma interaction in the host organ (organotropic metastasis). It has been reported that metastatic cancer cells derived from a particular tumour site present enhanced metastatic ability to specific organs, independent of the anatomy of blood and lymphatic vessels that drain the primary tumour site. There are many questions regarding how exosomes are directed to specific metastatic organs enabling organotrophic metastatic growth. For example, exosomes from breast cancer cells move to lung tissue in mouse models. Exosome biodistribution matched the organotropic metastatic spread in vitro in cell lines from various types of cancer such as breast and pancreatic cancer. This opens a new therapeutic window to target metastasis, which has not been achieved with conventional nanosystems. Besides, natural DDS seem to be unnoticed by the immune system. The large quantity of exosomes (1.5 billion exosomes per mL) in human blood allows their use as anti-cancer therapies. Nevertheless, they have not yet reached the clinics. Lack of standard isolation and loading protocols and important drawbacks regarding scale-up production, are still unsolved problems.Research should continue to explore new materials to improve DDS for anti-cancer therapies. An interesting alternative is to learn more about nature’s own delivery systems. In this regard, exosomes are a class of extracellular vesicles that contain proteins, nucleic acids, and lipids. They are the key players of numerous biological processes both pathologic and non-pathologic


Caregiving and care-sharing is a dynamic, stressful, and physically demanding responsibility, often leading to adverse psychological and physical outcomes. Caregiving for chronic illness and disease involves increasing complexity and scope of responsibilities and expectations. Utilizing strengths-based approaches and a variety of qualitative methods, this symposium highlights the many voices of care partners across the continuum of care; pre-, during and post-caregiving. First, Latimer and colleagues will present a case study of an older adult with multiple chronic illnesses, offering insight into anticipating care needs and coping with daily stressors of multi-morbidity in late life. Second, Morgan and colleagues will present findings from interviews with care partners on supporting the inner strength of those recently diagnosed with mild cognitive impairment. Third, Fox and colleagues share results from a dyadic, multi-modal intervention for pain management. Care partners who both experience persistent pain discuss changes in their relationship as a result of participating in the intervention together. Fourth, Wladkowski discusses caregiver’s perspectives on live discharge and re-enrollment into hospice care. Her findings demonstrate how the anticipated “end” isn’t always the end for ADRD caregivers. Fifth, Buck and colleagues will share caregivers’ responses to a psychotherapy intervention for the treatment of complicated grief post-death of the care partner. Discussant Deborah Waldrop will contextualize these findings and offer suggestions for future research and interventions to enhance care partners’ well-being across the continuum of chronic illness and care.


The prodromal stages of Alzheimer’s disease (AD) are the primary focus of research aimed at slowing disease progression. This study explores the influence of affective temperament on the motivation of people with mild cognitive impairment (MCI) and subjective cognitive decline (SCD) to participate in clinical trials. One hundred four subjects with MCI and SCD were screened for participation in pharmacological and non-pharmacological trials. Affective temperament was assessed based on the Temperament Evaluation of the Memphis, Pisa, Paris and San Diego (TEMPS) scale. Demographic variables and temperament subscales scores were compared between MCI and SCD patients and among patients participating in the pharmacological trial, the non-pharmacological trial and refusing participation. Twenty-one subjects consented to participate in the pharmacological trial, seventy consented to the non-pharmacological trial and thirteen refused to participate in any trial. Patients with SCD had greater education and more depressive temperamental traits than those with MCI. While older age, higher education and anxious temperament were negatively associated with participation in the pharmacological trial, irritable temperamental positively predicted pharmacological trial participation. In conclusion, temperamental features may affect the willingness of patients with MCI and SCD to take part in clinical trials and, especially, the choice to participate in pharmacological studies. The prevention and slowdown of cognitive impairment have assumed increasing importance. There is a critical need to develop pharmacological and non-pharmacological treatments that could be effective in the prodromal phases of Alzheimer’s disease (AD), in particular mild cognitive impairment (MCI) and subjective cognitive decline (SCD), to delay the onset of dementia . MCI, byGiven the importance of recruiting people with prodromal AD symptoms, future clinical trials must consider the factors that motivate patients with MCI and SCD to participate in research. The availability of transportation services offered by medical facilities, home visits, remuneration and a favorable attitude toward medical research have been found to be strongly associated with interest in enrolment in a sample of patients with and without cognitive impairment . AnotherWhen personality traits were investigated in the context of routine health screening, conscientiousness was associated with greater adherence to the program and a higher frequency of follow-up visits for adult subjects , whereasAlthough there are many studies on variables that affect involvement in screening and prevention, affective temperaments as motivating factors have not yet been investigated. Broadly speaking, temperament refers to individual constitutional differences in emotional and behavioral response that manifest early in life and remain relatively stable over time . AccordiSince temperamental features appear to be important in everyday choices, we hypothesized they might have a role in trial decision-making. In this study, we focused on examining the temperamental traits of individuals experiencing cognitive difficulties who demand medical help. Further, we investigated whether individuals with MCI and SCD were more likely to adhere to clinical trials depending on their temperamental features and if affective temperament influenced their decision to participate in pharmacological trials rather than non-pharmacological trials.Our sample consisted of 104 subjects (60 diagnosed with MCI and 44 with SCD) referred to the Memory Unit of the Neurological Clinic at Pisa University Hospital between January 2019 and December 2019 and screened for participation in a pharmacological and a non-pharmacological clinical trial. The pharmacological trial aimed to test monoclonal antibody treatment in people at a high risk of developing Alzheimer’s disease, including both MCI and SCD patients. The non-pharmacological study assessed the effectiveness of combined cognitive and physical training in slowing the progression of dementia. Exclusion criteria of both studies comprised any evidence of neurological pathologies, epilepsy, advanced neoplasia, recent cranial trauma, drug addiction, clinical evidence of depression or other psychiatric disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) . ExclusiAll subjects underwent a complete neuropsychological evaluation to assess several cognitive domains and a clinical evaluation, including the collection of medical history and a complete neurological examination. The diagnosis of MCI was obtained according to current diagnostic criteria , and SCDDemographic data, including age, gender and education years, were collected for all patients. Two self-report short Italian versions of the Temperament Evaluation in Memphis, Pisa and San Diego (TEMPS) scale were used to assess affective temperamental traits. The short TEMPS-Autoquestionnaire (TEMPS-A) , comprisn = 104). First, demographic variables and temperament subscales scores were compared between patients diagnosed with MCI and those diagnosed with SCD. Patients participating in pharmacological and non-pharmacological trials or refusing participation were then compared in the whole sample and the MCI group. Given the small number of patients with SCD refusing participation in trials (n = 2), only pharmacological and non-pharmacological trial groups were compared among patients with SCD. Pearson’s chi-squared test or, when appropriate, Fisher’s exact test were used for the comparison of categorical variables, with pairwise Fisher’s exact test used for post hoc comparisons. The Wilcoxon rank sum test and Kruskal–Wallis test were used, respectively, for two- and three-group comparisons of continuous variables, after excluding normality using Shapiro–Wilk test. The Dunn test was used for post hoc analyses. Finally, all variables, including diagnosis of SCD vs. MCI, were entered into a logistic regression model predicting participation in the pharmacological trial vs. adhesion to the non-pharmacological trial/refusal to participate. Backward stepwise model selection, based on minimizing the Akaike information criterion (AIC), was then applied. All analyses were performed using R Statistical Software . A statistical significance level of p < 0.05 was set in the analyses. False discovery rate (FDR) correction was applied to post hoc tests.Descriptive statistics were used to describe the demographic characteristics of the whole sample , and 58 patients (55.77%) were females. Education years were, on average, 12.48 ± 4.29 . Compared to patients with MCI, those with SCD had significantly more education years and showed a significantly higher depressive temperament score .FDR = 0.001) and those refusing participation (pFDR = 0.004).Overall, 21 subjects (10 with MCI and 11 with SCD) consented to participate in the pharmacological study, and 70 individuals (39 with MCI and 31 with SCD) adhered to the non-pharmacological trial. Thirteen patients (11 with MCI and 2 with SCD) refused participation in the proposed clinical trials. The three groups differed significantly in anxious temperament , with paFDR = 0.019) and those refusing participation (pFDR = 0.014).The same finding was confirmed among patients diagnosed with MCI . Even inIn addition, among patients diagnosed with SCD, those participating in the pharmacological trial were more frequently male, had a significantly higher score on the irritable temperament subscale and showed a significantly lower anxious temperament score compared to patients participating in the non-pharmacological trial .Finally, according to the multivariate logistic regression model, including all variables, education years and anxious temperament score were negatively associated with participation in the pharmacological trial, while irritable temperamental traits showed an opposite effect . After bIn this study, we explored if there were any differences in the affective temperaments of MCI and SCD patients involved in pharmacological and non-pharmacological clinical trials. Our results showed no differences in age and gender between SCD patients and MCI patients who were referred to the Memory Unit of the Neurological Clinic. In line with a previous study in which SCD patients had a higher education than MCI patients , our SCDDepressive temperamental traits may likely have a role in how patients perceive their memory abilities. Subjective memory complaints, in addition to being recognized as a predictor of cognitive decline and AD, have already been associated with depression and specific personality traits . The relAnxious temperament appears to discourage participation in pharmacological studies but not in non-pharmacological ones. In our sample, patients with MCI and SCD participating in non-pharmacological trials showed significantly more anxious traits than those participating in pharmacological trials. Our results are consistent with previous reports for cancer screening, observing that anxious traits may not necessarily favor participation in studies ,31,32. MConversely, irritable temperament tends to be associated with participation in pharmacological trials, at least in patients with SCD. To the best of our knowledge, no previous study investigated the relationship between irritable temperament or, more generally speaking, irritability and participation in clinical research. Irritable temperament has been previously associated with trait impulsivity . MoreoveNotably, anxious and irritable temperaments had divergent effects. Both temperamental features were found to mainly affect participation in the pharmacological trial. Indeed, anxious temperament prevented participation in the pharmacological trial but did not distinguish patients refusing participation in any trial from those taking part in the non-pharmacological one. On the other hand, irritable temperament was associated with participation in pharmacological research and, among SCD patients, distinguished between subjects adhering to the pharmacological vs. the non-pharmacological trial. Although modest positive associations were observed between anxious and irritable temperament in the general population (r = 0.24–0.28) ,47, the Older age, high education and anxious temperament are negative predictors of participating in a pharmacological trial, whereas having an irritable temperament is a positive predictor of participation in the pharmacological trial versus the non-pharmacological trial. Age was found to be a poor predictor of willingness to participate in a medical treatment trial in prior research on elderly individuals, with the intention to participate declining with age . Older aOur results are consistent with research investigating psychological factors that affect patients’ willingness to participate in phase I, II and III pharmacological trials. High exploratory tendency and perceived self-efficacy were observed in volunteers for phase I studies . MoreoveIdentifying an individual’s temperamental and personality features that affect their decision to participate in a clinical trial needs to be considered during the creation of recruitment and communication strategies. Particularly, the involvement of psychologists and social sciences experts can help overcome self-selection bias using personalized communication. Attempting to enroll the greatest number of patients, including those with personality traits that would prevent them from participating, would increase the overall number of participants and result in a more representative sample.Several methodological limitations of our study should be considered. A first limitation comes from the clinical setting in which patients were recruited, a tertiary referral neurological unit, where more complicated patients could have been overrepresented, thus undermining the representativeness of the sample and, together with the limited sample size, the generalizability of the results. Second, temperament was assessed using self-reported questionnaires that may be subjected to response biases due, for instance, to perceived social desirability, lack of introspective ability, influence of current affective states and exaggeration of symptoms to obtain assistance. Moreover, two different versions of the TEMPS scale were used, and scores were subsequently aggregated, limiting the comparability of our results with other studies. Further investigations are required to confirm our findings using informant-reported or clinician-rated instruments, possibly with established standardized norms, to assess affective temperament. Finally, although psychiatric disorders were considered among the exclusion criteria, no systematic, structured evaluation of psychopathology was used, making it possible that some patients with undiagnosed psychiatric conditions, such as patients with anxiety disorders scoring higher on anxious temperamental traits, were included. Whether psychopathology may interact with temperament variables to influence trial participation still needs to be explored.According to our preliminary findings, depressive temperament may be the reason for an early search for medical assistance in SCD patients since it increases the perception of how invalidating cognitive symptoms are. Temperamental features may also influence SCD and MCI patients’ willingness to participate in clinical trials. Participation in pharmacological studies may be encouraged by irritable temperament but discouraged by anxious temperamental traits. Temperament should be considered while designing clinical trials for individuals with prodromal AD because it influences health behavior and decision-making and plays a significant role in the attitude of patients towards participation. Building multidisciplinary teams, including clinicians, psychologists and social sciences experts, could help tailor communication strategies to each patient during the recruitment phase. For instance, a different communication approach may be required for patients showing highly anxious traits compared to those with predominantly irritable temperamental features. Further studies are warranted to develop temperament-sensitive recruitment procedures to include samples representative of the entire target population.